Fintel reports that Lowenthal Richard E has filed a 13D form with the SEC disclosing ownership of 7,422,432 shares of Silverback Therapeutics Inc (SBTX). This represents 7.9% of the company.
On Nov. 8, ARS closed its merger with Silverback. The combined company operates as ARS Pharmaceuticals, Inc.
Silverback Therapeutics, Inc. operates as a biotechnology company. The company discovers and develops novel and proprietary ImmunoTAC technology designed to create potent therapeutic molecules that can be systemically administered to patients. Silverback Therapeutics serves customers worldwide.
What are other large shareholders doing?
Orbimed Advisors LLC holds 8,740,887 shares.
K2 Principal Fund, L.P. owns 3,247,533 shares.
Rubric Capital Management LP owns 2,695,170 shares.
Nextech Invest AG owns 1,910,029 shares.
Nantahala Capital Management, LLC owns 1,249,863 shares.
What is the overall Fund Sentiment?
There are 164 funds or institutions reporting positions in Silverback Therapeutics Inc. This is a decrease of 18 owner(s) or 9.89%.
Average portfolio weight of all funds dedicated to Silverback Therapeutics Inc is 0.0687%, an increase of 42.1522%. Total shares owned by institutions increased in the last three months by 16.20% to 31,046,206 shares.
Fintel's Fund Sentiment Score is a quantitative model that ranks companies from zero to 100 based on Fund Sentiment. Fund Sentiment is important because it tells you if funds are buying or selling - particularly how the company ranks compared to other companies in the investing universe.
Click to see the Fintel Fund Sentiment Score for SBTX / Silverback Therapeutics Inc.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
